首页> Lung cancer (Amsterdam, Netherlands)> The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Christian,Rolfo

第一单位： Division of Medical Oncology, Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), Columbus, OH, USA. Electronic address: christian.rolfo@osumc.edu.

作者： Christian,Rolfo ^[1] ; David E,Gerber ^[2] ; Rupesh,Kotecha ^[3] ; Jeffrey P,Ward ^[4] ; Wallace,Akerley ^[5] ; Lukas,Weiss ^[6] ; Ariel,Naveh ^[7] ; Nadav,Shapira ^[7] ; Ticiana,Leal ^[8] ; Corey J,Langer ^[9] ; LUNAR study investigators

作者单位： Division of Medical Oncology, Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), Columbus, OH, USA. Electronic address: christian.rolfo@osumc.edu. ^[1] Harold C. Simmons Comprehensive Cancer Center, UT Texas Southwestern Medical Center, Dallas, TX, USA. ^[2] Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. ^[3] Washington University School of Medicine, St. Louis, MO, USA. ^[4] Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. ^[5] Paracelsus Medical University, Salzburg, Austria. ^[6] Novocure Ltd, Haifa, Israel. ^[7] Winship Cancer Institute at Emory University, Atlanta, GA, USA. ^[8] Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[9]

关键词 Body mass index Immune checkpoint inhibitor Non-small cell lung cancer PD-L1 inhibitor TTFields therapy Tumor Treating Fields